Larimar Therapeutics Inc (NASDAQ: LRMR) is 38.24% higher on its value in year-to-date trading and has touched a low of $2.18 and a high of $13.68 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The LRMR stock was last observed hovering at around $6.27 in the last trading session, with the day’s gains setting it 0.02%.
Currently trading at $6.29, the stock is -11.15% and -17.99% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.49 million and changing 0.32% at the moment leaves the stock -17.53% off its SMA200. LRMR registered 66.62% gain for a year compared to 6-month loss of -18.52%. The firm has a 50-day simple moving average (SMA 50) of $7.6068 and a 200-day simple moving average (SMA200) of $7.637275.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -9.10% gain in the last 1 month and extending the period to 3 months gives it a -17.56%, and is -0.79% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.99% over the week and 10.04% over the month.
Larimar Therapeutics Inc (LRMR) has around 42 employees, a market worth around $401.36M and $0.00M in sales. Distance from 52-week low is 188.53% and -54.02% from its 52-week high. The company has generated returns on investments over the last 12 months (-27.01%).
The EPS is expected to shrink by -70.91% this year
143.0 institutions hold shares in Larimar Therapeutics Inc (LRMR), with institutional investors hold 109.70% of the company’s shares. The shares outstanding are 43.91M, and float is at 37.27M with Short Float at 8.92%. Institutions hold 108.11% of the Float.
The top institutional shareholder in the company is DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with over 21.23 million shares valued at $153.93 million. The investor’s holdings represent 39.6461 of the LRMR Shares outstanding. As of 2024-06-30, the second largest holder is RA CAPITAL MANAGEMENT, L.P. with 6.05 million shares valued at $43.83 million to account for 11.2884 of the shares outstanding. The other top investors are JANUS HENDERSON GROUP PLC which holds 4.38 million shares representing 8.1738 and valued at over $31.63 million, while GOLDMAN SACHS GROUP INC holds 8.0906 of the shares totaling 4.33 million with a market value of $31.41 million.
Larimar Therapeutics Inc (LRMR) Insider Activity
The most recent transaction is an insider purchase by Hamilton Thomas Edward, the company’s Director. SEC filings show that Hamilton Thomas Edward bought 57,208 shares of the company’s common stock on Feb 16 ’24 at a price of $8.74 per share for a total of $0.5 million. Following the purchase, the insider now owns 0.56 million shares.
Larimar Therapeutics Inc disclosed in a document filed with the SEC on Feb 16 ’24 that Flynn James E (Director) bought a total of 4,290,617 shares of the company’s common stock. The trade occurred on Feb 16 ’24 and was made at $8.74 per share for $37.5 million. Following the transaction, the insider now directly holds 6.15 million shares of the LRMR stock.
Still, SEC filings show that on Feb 14 ’24, THOMAS FRANK E (Director) acquired 2,000 shares at an average price of $11.00 for $22000.0. The insider now directly holds 2,000 shares of Larimar Therapeutics Inc (LRMR).
